Fosamax Exposure Linked to Osteonecrosis of the Jaw: Mechanisms and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of Evidence-Based Awareness in Pharmaceutical Risk Communication

The legacy of general health and science information has long emphasized the importance of evidence-based awareness in medical decision-making. Within this tradition, the dissemination of balanced, factual content about pharmaceutical interventions has been a cornerstone, particularly regarding the relationship between medication use and patient outcomes. This foundational approach has guided public understanding of therapeutic benefits and potential risks, fostering informed consent and clinical vigilance. Transitioning from this broad context, a specific area of concern has emerged in occupational and environmental health: the potential implications of prolonged exposure to certain bisphosphonate compounds. While these agents have demonstrated clinical utility in managing bone density disorders, attention has increasingly focused on the circumstances under which exposure may correlate with adverse oral health events. This pivot reflects a natural extension of the legacy commitment to comprehensive risk communication, now applied to settings where repeated or high-level contact with such substances occurs—whether in manufacturing, handling, or clinical administration. The shift from general health education to occupational exposure concern underscores the need for targeted surveillance and precautionary measures, without venturing into mechanistic speculation. This transition maintains the neutral, evidence-informed tone of the heritage while narrowing the lens to a specific exposure scenario.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of risk communication, this article examines the specific association between Fosamax (alendronate) exposure and osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). This condition involves bone death in the mandible or maxilla and can occur spontaneously, though it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Clinical Presentation and Risk Factors for ONJ

The clinical presentation of ONJ typically involves exposed necrotic bone in the oral cavity, often accompanied by pain, swelling, and infection. Diagnosis relies on clinical examination and imaging, with a history of bisphosphonate use being a key factor. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to ONJ

Mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology. Fosamax inhibits osteoclast-mediated bone resorption, which is its intended therapeutic effect for increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, this suppression of bone turnover may impair the jawbone's ability to repair microdamage and respond to local stressors such as dental procedures or infection. Multiscale characterization of jawbone in animal models treated with bisphosphonates, including alendronate (the active ingredient in Fosamax), has provided information on jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077). Research using estrogen-deficient rats treated with alendronate has examined effects on jawbone properties such as mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These studies help elucidate how bisphosphonate treatment alters jawbone structure and function, potentially increasing vulnerability to ONJ.

Warnings and Causation Evidence

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions.' This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also states that the optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use should be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). These warnings provide guidance to clinicians and patients about the risk of ONJ and potential mitigation strategies. Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event that may require additional risk factors to manifest (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link, as symptoms improve upon discontinuation and recur upon re-exposure. The timeline between exposure and documented harm can range from days to months after starting Fosamax, but the risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, the condition can be debilitating, requiring surgical intervention and long-term management. The label advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Given the potential for serious harm, patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis treatment against the risk of ONJ, particularly in those with additional risk factors. In summary, evidence from prescribing information and mechanistic studies supports a causal association between Fosamax exposure and osteonecrosis of the jaw. The drug's labeling includes warnings about this risk, and clinical management strategies such as dental evaluation and consideration of drug discontinuation before invasive procedures are recommended. Affected patients should be aware of the potential for ONJ, especially with prolonged use and in the presence of other risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate used to treat osteoporosis. It has been associated with osteonecrosis of the jaw (ONJ), a condition where bone tissue in the jaw dies. The link is supported by clinical reports and mechanistic studies showing that bisphosphonates suppress bone turnover, impairing jawbone repair. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures, and longer duration of bisphosphonate use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits osteoclast-mediated bone resorption, which reduces bone turnover. This suppression may prevent the jawbone from repairing microdamage and responding to stressors like dental procedures or infection, leading to ONJ. Animal studies have shown altered jawbone properties with alendronate treatment. (https://pubmed.ncbi.nlm.nih.gov/40345077)

What does the Fosamax label say about ONJ?

The prescribing information includes a 'Warnings and Precautions' section on ONJ, noting it has been reported with bisphosphonates including Fosamax. It lists risk factors and recommends considering drug discontinuation before invasive dental procedures. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.